CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2012-09-03): Raloxifene aids HCV therapy in some postmenopausal women

Drug & Device Development

Raloxifene aids HCV therapy in some postmenopausal women

Last Updated: 2012-09-03 12:00:24 -0400 (Reuters Health)

NEW YORK (Reuters Health) - The addition of raloxifene to standard treatment for hepatitis C virus (HCV) infection in postmenopausal women appears to improve outcome in many, according to Japanese researchers.

Dr. Jun Hayashi of Kyushu University Hospital and colleagues note that because pegylated interferon therapy is more effective in younger than older women it suggests a potential link to reduced estrogen secretion. In addition, early menopause has been reported to be the most predictive factor for failure to achieve a sustained viral response (SVR).

Raloxifene is an oral selective estrogen receptor modulator. Such agents have been suggested to function as estrogen agonists that directly protect hepatocytes and control liver fibrosis.

In a paper online August 13 in the Journal of Hepatology, the researchers report that to examine whether this might be of help, they studied 127 postmenopausal women with genotype 1b chronic HCV.

They were randomized to treatment with pegylated interferon alpha 2a and ribavirin with or without raloxifene 60 mg per day. Planned treatment duration was 48 weeks and all patients were followed for 24 weeks after cessation of treatment.

At this point, the SVR rate was significantly higher in the raloxifene group (61.3% vs. 34.4%, p=0.0051).This was also true of end of treatment response (88.7% versus 68.9%, p=0.0132).

Comparison by interleukin-28B genotype showed that response was significantly greater in the raloxifene patients with interleukin-28B TT compared to their counterparts who did not receive the agent (72.5% vs. 39.2%, p=0.0014). This was not true of carriers of the minor IL28B allele.

Summing up, Dr. Hayashi told Reuters Health by email that the raloxifene-mediated improvement in response is limited to patients homozygous for the major allele of IL28B, and studies are needed in other ethnic groups. Yet the agent "may be a promising candidate as an adjuvant in the antiviral treatment of postmenopausal women with chronic hepatitis C."

SOURCE: http://bit.ly/OzkYiQ

J Hepatol 2012.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.